Cargando…

Effectiveness and safety of secukinumab for psoriasis in real-world practice: analysis of subgroups stratified by prior biologic failure or reimbursement

BACKGROUND: Little is known about the treatment outcomes of secukinumab in clinical practice, which differ from those in clinical trials. The effectiveness of biologics may differ in psoriasis patients with previous biologics exposure. The objective of this study was to investigate the real-world ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Ger, Tzong-Yun, Huang, Yu-Huei, Hui, Rosaline Chung-yee, Tsai, Tsen-Fang, Chiu, Hsien-Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6472156/
https://www.ncbi.nlm.nih.gov/pubmed/31024679
http://dx.doi.org/10.1177/2040622319843756
_version_ 1783412188817391616
author Ger, Tzong-Yun
Huang, Yu-Huei
Hui, Rosaline Chung-yee
Tsai, Tsen-Fang
Chiu, Hsien-Yi
author_facet Ger, Tzong-Yun
Huang, Yu-Huei
Hui, Rosaline Chung-yee
Tsai, Tsen-Fang
Chiu, Hsien-Yi
author_sort Ger, Tzong-Yun
collection PubMed
description BACKGROUND: Little is known about the treatment outcomes of secukinumab in clinical practice, which differ from those in clinical trials. The effectiveness of biologics may differ in psoriasis patients with previous biologics exposure. The objective of this study was to investigate the real-world effectiveness and safety of secukinumab therapy and analyze subgroups stratified by reimbursement or prior biologic failure. METHODS: This retrospective multicenter study collected data from a cohort of 118 consecutive patients who received secukinumab treatment between December 2015 and March 2018. Effectiveness was evaluated by degree of improvement in the Psoriasis Area and Severity Index (PASI) scores. Adverse events and reasons for discontinuation were also recorded. RESULTS: The mean PASI improvement rate at weeks 4, 12, 24, and 36 was 63.5%, 77.7%, 78.7%, and 76.0%, respectively. Compared with reimbursed patients, nonreimbursed patients had a significantly lower baseline PASI and a shorter mean disease duration of psoriasis; they were more frequently biologic-naïve, had used less prior traditional antipsoriatic drugs and were more likely to be treated with secukinumab 150 mg. The effectiveness of secukinumab in nonreimbursed patients was superior despite higher discontinuation rates. Compared with patients without prior biologic failure, patients with prior biologic failure had a significantly lower mean PASI improvement at weeks 12, 24, 36, and 48. The decline in response rates to secukinumab tended to be more pronounced for patients who failed ustekinumab than tumor necrosis factor-α inhibitors. Moreover, the number of prior biologic failures was associated with a decreased response rate and increased likelihood of secondary loss of effectiveness of secukinumab therapy. CONCLUSION: In a real-life clinical setting, the characteristics of nonreimbursed patients receiving secukinumab treatment differed from those of reimbursed patients. The PASI improvement for secukinumab was substantial but lower than that in clinical trials. The number and classes of prior biologic failures impact the treatment response to secukinumab.
format Online
Article
Text
id pubmed-6472156
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-64721562019-04-25 Effectiveness and safety of secukinumab for psoriasis in real-world practice: analysis of subgroups stratified by prior biologic failure or reimbursement Ger, Tzong-Yun Huang, Yu-Huei Hui, Rosaline Chung-yee Tsai, Tsen-Fang Chiu, Hsien-Yi Ther Adv Chronic Dis Original Research BACKGROUND: Little is known about the treatment outcomes of secukinumab in clinical practice, which differ from those in clinical trials. The effectiveness of biologics may differ in psoriasis patients with previous biologics exposure. The objective of this study was to investigate the real-world effectiveness and safety of secukinumab therapy and analyze subgroups stratified by reimbursement or prior biologic failure. METHODS: This retrospective multicenter study collected data from a cohort of 118 consecutive patients who received secukinumab treatment between December 2015 and March 2018. Effectiveness was evaluated by degree of improvement in the Psoriasis Area and Severity Index (PASI) scores. Adverse events and reasons for discontinuation were also recorded. RESULTS: The mean PASI improvement rate at weeks 4, 12, 24, and 36 was 63.5%, 77.7%, 78.7%, and 76.0%, respectively. Compared with reimbursed patients, nonreimbursed patients had a significantly lower baseline PASI and a shorter mean disease duration of psoriasis; they were more frequently biologic-naïve, had used less prior traditional antipsoriatic drugs and were more likely to be treated with secukinumab 150 mg. The effectiveness of secukinumab in nonreimbursed patients was superior despite higher discontinuation rates. Compared with patients without prior biologic failure, patients with prior biologic failure had a significantly lower mean PASI improvement at weeks 12, 24, 36, and 48. The decline in response rates to secukinumab tended to be more pronounced for patients who failed ustekinumab than tumor necrosis factor-α inhibitors. Moreover, the number of prior biologic failures was associated with a decreased response rate and increased likelihood of secondary loss of effectiveness of secukinumab therapy. CONCLUSION: In a real-life clinical setting, the characteristics of nonreimbursed patients receiving secukinumab treatment differed from those of reimbursed patients. The PASI improvement for secukinumab was substantial but lower than that in clinical trials. The number and classes of prior biologic failures impact the treatment response to secukinumab. SAGE Publications 2019-04-17 /pmc/articles/PMC6472156/ /pubmed/31024679 http://dx.doi.org/10.1177/2040622319843756 Text en © The Author(s), 2019 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research
Ger, Tzong-Yun
Huang, Yu-Huei
Hui, Rosaline Chung-yee
Tsai, Tsen-Fang
Chiu, Hsien-Yi
Effectiveness and safety of secukinumab for psoriasis in real-world practice: analysis of subgroups stratified by prior biologic failure or reimbursement
title Effectiveness and safety of secukinumab for psoriasis in real-world practice: analysis of subgroups stratified by prior biologic failure or reimbursement
title_full Effectiveness and safety of secukinumab for psoriasis in real-world practice: analysis of subgroups stratified by prior biologic failure or reimbursement
title_fullStr Effectiveness and safety of secukinumab for psoriasis in real-world practice: analysis of subgroups stratified by prior biologic failure or reimbursement
title_full_unstemmed Effectiveness and safety of secukinumab for psoriasis in real-world practice: analysis of subgroups stratified by prior biologic failure or reimbursement
title_short Effectiveness and safety of secukinumab for psoriasis in real-world practice: analysis of subgroups stratified by prior biologic failure or reimbursement
title_sort effectiveness and safety of secukinumab for psoriasis in real-world practice: analysis of subgroups stratified by prior biologic failure or reimbursement
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6472156/
https://www.ncbi.nlm.nih.gov/pubmed/31024679
http://dx.doi.org/10.1177/2040622319843756
work_keys_str_mv AT gertzongyun effectivenessandsafetyofsecukinumabforpsoriasisinrealworldpracticeanalysisofsubgroupsstratifiedbypriorbiologicfailureorreimbursement
AT huangyuhuei effectivenessandsafetyofsecukinumabforpsoriasisinrealworldpracticeanalysisofsubgroupsstratifiedbypriorbiologicfailureorreimbursement
AT huirosalinechungyee effectivenessandsafetyofsecukinumabforpsoriasisinrealworldpracticeanalysisofsubgroupsstratifiedbypriorbiologicfailureorreimbursement
AT tsaitsenfang effectivenessandsafetyofsecukinumabforpsoriasisinrealworldpracticeanalysisofsubgroupsstratifiedbypriorbiologicfailureorreimbursement
AT chiuhsienyi effectivenessandsafetyofsecukinumabforpsoriasisinrealworldpracticeanalysisofsubgroupsstratifiedbypriorbiologicfailureorreimbursement